Home > Publications database > Intrathecal activation of CD8+ memory T cells in IgG4-related disease of the brain parenchyma. > print |
001 | 169822 | ||
005 | 20240229133656.0 | ||
024 | 7 | _ | |a 10.15252/emmm.202113953 |2 doi |
024 | 7 | _ | |a pmid:34254741 |2 pmid |
024 | 7 | _ | |a 1715-4684 |2 ISSN |
024 | 7 | _ | |a 1757-4676 |2 ISSN |
024 | 7 | _ | |a 1757-4684 |2 ISSN |
024 | 7 | _ | |a altmetric:109298911 |2 altmetric |
037 | _ | _ | |a DKFZ-2021-01569 |
041 | _ | _ | |a English |
082 | _ | _ | |a 610 |
100 | 1 | _ | |a Friedrich, Mirco |0 P:(DE-He78)1cab354af0aff62f1b8d569477b4be4c |b 0 |e First author |u dkfz |
245 | _ | _ | |a Intrathecal activation of CD8+ memory T cells in IgG4-related disease of the brain parenchyma. |
260 | _ | _ | |a Heidelberg |c 2021 |b EMBO Press |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1698997531_23207 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
500 | _ | _ | |a #EA:D170#LA:D170# / 2021 Aug 9;13(8):e13953 / HI-TRON |
520 | _ | _ | |a IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder signified by aberrant infiltration of IgG4-restricted plasma cells into a variety of organs. Clinical presentation is heterogeneous, and pathophysiological mechanisms of IgG4-RD remain elusive. There are very few cases of IgG4-RD with isolated central nervous system manifestation. By leveraging single-cell sequencing of the cerebrospinal fluid (CSF) of a patient with an inflammatory intracranial pseudotumor, we provide novel insights into the immunopathophysiology of IgG4-RD. Our data illustrate an IgG4-RD-associated polyclonal T-cell response in the CSF and an oligoclonal T-cell response in the parenchymal lesions, the latter being the result of a multifaceted cell-cell interaction between immune cell subsets and pathogenic B cells. We demonstrate that CD8+ T effector memory cells might drive and sustain autoimmunity via macrophage migration inhibitory factor (MIF)-CD74 signaling to immature B cells and CC-chemokine ligand 5 (CCL5)-mediated recruitment of cytotoxic CD4+ T cells. These findings highlight the central role of T cells in sustaining IgG4-RD and open novel avenues for targeted therapies. |
536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
650 | _ | 7 | |a CSF single-cell sequencing |2 Other |
650 | _ | 7 | |a IgG4-related disease |2 Other |
650 | _ | 7 | |a cytotoxic T helper cell |2 Other |
650 | _ | 7 | |a inflammatory pseudotumor |2 Other |
650 | _ | 7 | |a pathogenic B-cell |2 Other |
700 | 1 | _ | |a Kehl, Niklas |0 P:(DE-He78)fad274ed48f42202270f60e22b0bcdd1 |b 1 |u dkfz |
700 | 1 | _ | |a Engelke, Niko |b 2 |
700 | 1 | _ | |a Kraus, Josephine |b 3 |
700 | 1 | _ | |a Lindner, Katharina |0 P:(DE-He78)9c599f876c762bc78d289674c15ba4a5 |b 4 |u dkfz |
700 | 1 | _ | |a Münch, Philipp |0 P:(DE-He78)66bc424b1c5322674c5f9c9d7131f760 |b 5 |u dkfz |
700 | 1 | _ | |a Mildenberger, Iris |0 P:(DE-He78)7daa75b87e6d6e291016ecb54f60b6b3 |b 6 |u dkfz |
700 | 1 | _ | |a Groden, Christoph |b 7 |
700 | 1 | _ | |a Gass, Achim |b 8 |
700 | 1 | _ | |a Etminan, Nima |b 9 |
700 | 1 | _ | |a Fatar, Marc |b 10 |
700 | 1 | _ | |a von Deimling, Andreas |0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144 |b 11 |u dkfz |
700 | 1 | _ | |a Reuss, David |0 P:(DE-He78)d5149ffd74f42a2fa87a086d66645aaa |b 12 |u dkfz |
700 | 1 | _ | |a Platten, Michael |0 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5 |b 13 |u dkfz |
700 | 1 | _ | |a Bunse, Lukas |0 P:(DE-He78)e579130c57e8c686ed1c2dedfa595985 |b 14 |e Last author |u dkfz |
773 | _ | _ | |a 10.15252/emmm.202113953 |0 PERI:(DE-600)2485479-7 |n 8 |p e13953 |t EMBO molecular medicine |v 13 |y 2021 |x 1757-4684 |
909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:169822 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)1cab354af0aff62f1b8d569477b4be4c |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)fad274ed48f42202270f60e22b0bcdd1 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)9c599f876c762bc78d289674c15ba4a5 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)66bc424b1c5322674c5f9c9d7131f760 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)7daa75b87e6d6e291016ecb54f60b6b3 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)d5149ffd74f42a2fa87a086d66645aaa |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-He78)e579130c57e8c686ed1c2dedfa595985 |
913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
913 | 0 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-314 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Tumor immunology |x 0 |
914 | 1 | _ | |y 2021 |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EMBO MOL MED : 2019 |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2021-02-04 |
915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Peer review |d 2021-02-04 |
915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-02-04 |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-02-04 |
915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EMBO MOL MED : 2019 |d 2021-02-04 |
915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-02-04 |
915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-02-04 |
915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2021-02-04 |
920 | 1 | _ | |0 I:(DE-He78)D170-20160331 |k D170 |l KKE Neuroimmunologie und Hirntumorimmunologie |x 0 |
920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
920 | 1 | _ | |0 I:(DE-He78)B300-20160331 |k B300 |l KKE Neuropathologie |x 2 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-He78)D170-20160331 |
980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
980 | _ | _ | |a I:(DE-He78)B300-20160331 |
980 | _ | _ | |a UNRESTRICTED |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|